Stem-cell therapy for peripheral arterial occlusive disease

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Stem Cell Therapy

Background:

• Limb ischemia poses a significant clinical challenge, often leading to amputation.
• Developing effective and safe cell-based therapies for ischemic conditions is a critical research area.

Purpose of the Study:

• To evaluate the therapeutic potential of human cord blood-mononuclear cells (HCB-MNCs) for limb ischemia.
• To assess both the efficacy in preclinical models and the safety in human subjects.

Main Methods:

• A dose-response animal study using a canine limb ischemia model to evaluate angiogenic responses to HCB-MNCs.
• A case series of seven patients with thromboangiitis obliterans treated with HCB-MNCs, monitoring for graft-versus-host disease and other complications.

Main Results:

• HCB-MNC transplantation significantly increased capillary density, angiogenic gene expression, and angiogenic factors in animal ischemic limbs.
• No instances of graft-versus-host disease or cardiac/cerebral complications were reported in the seven treated patients during the follow-up period.

Conclusions:

• Preliminary findings suggest HCB-MNCs are a potentially safe source of stem cells for treating ischemic limbs.
• Further extensive clinical research is warranted to confirm long-term safety and efficacy of HCB-MNC transplantation.